Diagnosing primary ciliary dyskinesia in Australian adults: 10 years of testing Authors: P. J. Robinson Published: 2026 ABSTRACT AbstractPrimary ciliary dyskinesia (PCD) is a rare inherited disorder characterised by impaired ciliary function, leading to chronic upper and lower airway disease from early life. Limited awareness of the condition contributes to delayed diagnosis, with some individuals first diagnosed in adulthood following specialised testing. We describe 91 adults referred to the PCD diagnostic service at the Royal Children's Hospital in Melbourne, Australia over a 10‐year period. Twenty‐eight adults were diagnosed with PCD (31% referrals). The most common reason for referral was bronchiectasis. These findings highlight the importance of considering PCD in adults presenting with features suggestive of chronic airway disease, particularly bronchiectasis. Discussion Primary ciliary dyskinesia (PCD) is an uncommon condition usually inherited in an autosomal recessive manner. It is characterised by impaired respiratory epithelial ciliary function leading to chronic suppurative upper and lower disease, including rhinitis, sinusitis and progressive bronchiectasis. 1 Symptoms are frequently present from birth, with an estimated 80% of infants having a form of neonatal respiratory distress. Nevertheless, diagnosis is often delayed due to limited awareness of the condition and the misattribution of common symptoms, including wet cough and nasal discharge as due to more common non‐genetic conditions. 2 Failure to consider PCD in the light of these paediatric symptoms may result in patients reaching adult age without diagnosis. Many adults with chronic cough present to bronchiectasis clinics for evaluation of underlying causes such as cystic fibrosis or immunological disorders; however, PCD is often overlooked. Given the inherited nature of PCD and its characteristic features not typically seen in other causes of bronchiectasis – such as hearing loss, chronic sinusitis and infertility – establishing the diagnosis remains important, even in adulthood. Diagnosis of PCD requires testing in specialised centres and includes a range of detailed tests of ciliary structure and function, including high‐speed video microscopy assessment of ciliary beat pattern and frequency and electron microscopic assessment of ciliary ultrastructure supported by genetic testing. The PCD diagnostic service at the Royal Children's Hospital (RCH), Melbourne, established in 2013, is currently one of only two full diagnostic services for PCD in Australia. Testing for PCD in our service follows the diagnostic guidelines published by the European Respiratory Society and American Thoracic Society. 3 , 4 The RCH‐based service receives referrals from Victoria, Tasmania, South Australia and the southern part of the Northern Territory. In this report we describe the adults referred to our service for testing, their presenting symptoms and outcomes of their testing. The PCD diagnostic outpatient clinic at the RCH, Melbourne, Australia, accepts referrals for patients of all ages from specialists including respiratory physicians, ENT surgeons, general physicians and paediatricians. Referrals are generally not accepted from general practitioners or family doctors unless there is a strong suggestion of PCD as a possible diagnosis, such as the presence of heterotaxy or family history. Details of all patients who had PCD testing performed between January 2015 and September 2025 were extracted from the hospital's electronic medical records. PCD testing performed included measurement of exhaled nasal nitric oxide, high‐speed video microscopy assessment of ciliary beating and beat pattern, electron microscopic assessment of ciliary ultrastructure and immunofluorescence studies for major protein groups found in PCD. Immunofluorescence studies were only performed after 2019. 4 From the extracted files, patients over 18 years of age at the time of referral were identified. Every adult patient's file was then reviewed to identify the principal reason for referral and the subsequent result of testing. The study received governance approval from the Royal Children's Human Research Ethics committee (Project 4708) (Fig. 1). Number of adults by age referred for PCD testing at PCD diagnostic unit at Royal Children's Hospital, Melbourne, between 2015 and 2025. PCD, primary ciliary dyskinesia. From January 2015 to September 2025, 897 patients were referred to the diagnostic service. Ninety‐one were over the age of 18 at the time of referral. The average age was 36.8 ± 14 years (range 18–78 years). There were 42 males and 49 females. The commonest cause for referral was the presence of bronchiectasis (47 patients, 52% of referrals). Upper airway symptoms, including chronic rhinosinusitis, alone accounted for 11 referrals (12%), while 10 referrals were for combined upper and lower airway symptoms (11%). Other reasons for referral included chronic cough, family history of PCD and a previous diagnosis of PCD (Table 1). Table 1Principal reason for referral of adults to the PCD diagnostic unit at the Royal Children's Hospital between 2015 and 2025Principal reason for referralNumber of adults referredNumber of PCD cases in referred adultsBronchiectasis4713 (28%)Upper airway symptoms only113 (27%)Upper and lower airway symptoms103 (30%)Situs85 (62%)Cough90 (0%)Family history PCD64 (66%)Previous Dx10 (0%)Total screened9128 (31%) Principal reason for referral of adults to the PCD diagnostic unit at the Royal Children's Hospital between 2015 and 2025 Seventy‐six referrals were received from respiratory physicians (84%), six from ENT surgeons (7%), six from general practitioners (7%), and two from general physicians (2%). Six patients were referred due to a family history of PCD and eight patients due to the presence of heterotaxy. Of the 91 adult patients tested, 28 were diagnosed with PCD (31% of referrals). Among patients referred for bronchiectasis, 28% were diagnosed with PCD, compared with 27% of those referred primarily for upper airway symptoms. The presence of heterotaxy or a family history of PCD was associated with a high diagnostic yield (62% and 66%, respectively). Of the 28 patients who were found to have PCD, 27 (96%) had abnormalities detectable on high‐speed videography. Of the 25 samples which were processed for electron microscopic analysis of ciliary ultrastructure, 24 (96%) showed diagnostic abnormalities. Of the 16 patients whose samples were processed using immunofluorescence studies, 15 (94%) were diagnostic for PCD. Twenty patients performed exhaled nasal nitric oxide measurements, and 19 (95%) were in the low range, suggestive of PCD. The main finding of our study is the high diagnostic yield in the adult group, with 28 of 91 referrals (31%) diagnosed with PCD, which is considerably higher than that observed in the paediatric group tested in our service, where 10% of referrals are diagnosed with PCD. The diagnosis of PCD is often delayed, and although symptoms typically appear at a young age, it is not uncommon to see patients presenting in adult life with symptoms of suppurative airway disease consistent with PCD, yet without a clear diagnosis. While more common conditions need to be excluded first, the presence or history of symptoms present from early on in life may indicate the need for consideration of PCD as a diagnosis and the need for referral for testing. Referral should only be considered once more common conditions such as cystic fibrosis, immunodeficiencies, post‐infective bronchiectasis and allergic upper airway conditions have been excluded. The incidence of positive results in our adult group is significantly higher than in the paediatric group from our service (10% positive referrals). Our findings are similar to those obtained by Kouis et al. in a meta‐analysis of consecutive case referrals for PCD testing. They reported a diagnostic rate of 32% of referred cases; however, their analysis included 11 separate reports from multiple sites with diverse referral practises and included patients of all ages, making direct comparison with our single‐centre, adult‐focused data difficult. 5 There are several important reasons to make the diagnosis of PCD in adults, and particularly in the presence of bronchiectasis as a presenting symptom. As an inherited condition, genetic counselling may be important for young adults considering reproductive choices. Similarly, review of related family members for similar symptoms may also warrant referral for testing. As PCD is a suppurative condition affecting not only the lower airways but also the upper airway, sinuses and eustachian tubes, review by an ENT surgeon, as well as audiology testing for possible hearing loss, would be important. Beyond the respiratory tract, it is estimated that 85% of males with PCD may be infertile due to sperm dysmotility; genetic counselling would be appropriate for younger adult males. Likewise, recognition of reduced fertility found in women, secondary to ectopic pregnancies, would also require specialist supervision. 6 The delay in diagnosis of a condition which frequently causes symptoms from very early on in life most likely may cause significant stress to the patient. Behan interviewed 20 parents and patients with PCD and reported that in 35% of cases, over 40 medical consultations had occurred before the diagnosis of PCD had been made. In an associated survey of over 300 people with PCD, a positive diagnosis was described by many as resulting in a significant sense of validation that their symptoms were a result of a specific condition. 7 Structural lung changes in PCD, seen on CT scanning, include bronchial wall thickening and bronchiectasis. 8 The majority of changes are identified in the lower and middle lobes with significant upper lobe sparing. As most airway clearance techniques are performed with the patient in the upright position, it may be necessary to alter this position to optimise lower lobe drainage in patients with PCD. Mucolytic therapy found beneficial in other forms of bronchiectasis has not been shown to be effective in trials in PCD. 9 In recent years, mutation‐specific corrective therapies for PCD have been developed and reached phase 1–2 clinical trials. It is thus important to make the diagnosis of PCD, including confirmatory genetic confirmation, to allow access to these potential new therapies. 10 Several predictive tools to aid in the referral of appropriate patients for PCD testing have been developed. Behan developed the Primary Ciliary Dyskinesia Rule score for the prediction of patients who should be referred for testing. 11 The score uses seven factors to consider, with a total maximum overall score of 14. Scores over 10 have a 90% probability of a subsequent positive diagnosis of PCD. The high incidence of suggestive symptoms presenting early on in life – neonatal respiratory distress and admission to special care nursery – limit its use in adults as many may have limited, if any, recollection of issues surrounding their birth. Leigh and colleagues from the USA suggest a simpler approach to predicting the need for testing by using a four‐factor score, including unexplained neonatal respiratory distress, early onset, year‐round wet cough, early‐onset year‐round nasal congestion and laterality defect, with the suggestion that if two or more features are present, testing for PCD should be performed. 12 While neonatal respiratory distress is included in this score, adults presenting with non‐seasonal upper and lower airway symptoms are an appropriate patient group to refer for testing. Accordingly, there is a recognised need for the development of an adult‐specific version of the PICADAR score. In summary, referral of adult patients with symptoms suggestive of PCD is important, and current referral practices demonstrate a high diagnostic yield.